NCT06861413View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

PHASE1CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

May 5, 2025

Study Completion Date

May 5, 2025

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-828

Tablets for Oral Administration.

DRUG

VX-828

Suspension for Oral Administration.

Trial Locations (1)

85283

Celerion - Tempe, Tempe

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY